Appreciate the explanation and hope they've considered it carefully. I guess I'm a little "gun-shy" after the previous bungles in the leronlimab testing jungle. Don't want to be looking back wondering why we didn't cover some base or other.
Hope Recknor and Kelly are sure this is the correct move - not sure how many do-overs we can get awy with.
Market Data 
Markets 
AI
